Study of the Effect of Sedatives on Continuous Positive Airway Pressure Titration and Short Term Therapy Compliance | ||||
| The Medical Journal of Cairo University | ||||
| Article 3, Volume 87, March, March 2019, Page 19-25 PDF (618.16 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2019.52298 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| ROFAIDA E.M. EL-GENDY, M.Sc.; HODA M. BAHR, M.D.; MAI A. EISSA, M.D.; AHMED Sh. MOHAMED, M.D.; REHAM A. AMER, M.D. | ||||
| The Departments of Chest* and Neuropsychiatry**, Faculty of Medicine, Tanta University | ||||
| Abstract | ||||
| Background: Obstructive Sleep Apnea (OSA) is the most common form of sleep disordered breathing and represents a major public health problem. It is caused by repetitive collapse of a narrow upper airway during sleep with periodic cessation of breathing (for more than 10 seconds). These events usually result in fragmented sleep, intermittent hypoxia and lead to excessive daytime sleepiness. Aim of Study: We aimed to evaluate the effect of sedatives, as a method to improve over night continuous positive airway pressure titration, short-term therapy compliance, and outcomes in patients with newly diagnosed obstructive sleep apnea. Patients and Methods: 40 Subjects in this randomized, double-blind, placebo-controlled trial were divided to group I received 3mg eszopiclone and group II received placebo within 60min prior to the start of CPAP titration (at lights out) and, for 2 weeks as a combined therapy with CPAP before sleep, we compared the quality of CPAP titrations and Adher-ence to CPAP (primary outcome) during the first 4 weeks of therapy between the two groups, and evaluated improvements in symptoms (secondary outcomes) after 2 and 4 weeks of therapy. Results: Eszopiclone significantly improved sleep titration quality (increased sleep efficiency, increased total sleep time, decreased total arousal index, decreased CPAP pressure, decreased AHI at the highest CPAP pressure) and significantly & rapidly improved short term compliance (% of night CPAP used, mean hours/nights CPAP used, % of nights CPAP used >4 hours) and functional and behavioral outcomes, compared with placebo group. Conclusion: Nonbenzodiazepine hypnotics (eszopiclone) are safe and relatively inexpensive and have the potential to improve the quality of polysomnograms or prevent studies from needing to be repeated. A short course of nonbenzodi-azepines is a simple option that may facilitate better CPAP tolerance, improve therapeutic adherence, and reduce the rate of self-discontinuation of therapy. Good CPAP adherence lead to better functional outcomes. | ||||
| Keywords | ||||
| Obstructive sleep apnea; Eszopiclone | ||||
|
Statistics Article View: 203 PDF Download: 230 |
||||
